

# 新規な疎水性 / 親水性ハイブリッド ODS固定相を用いた 血漿試料直接注入による 血中ランソプラゾール濃度測定法

---

- 立木秀尚<sup>1</sup>, 矢澤到<sup>2</sup>  
東和薬品株式会社<sup>1</sup>, インタクト株式会社<sup>2</sup>



TOWA PHARMACEUTICAL CO., LTD.

# 概要

---

前処理に関するアンケート



**Novel Hydrophobic/Hydrophilic Hybrid ODS Column**



**Direct Injection LC-MS/MS Analysis**




**Clinical Trial**



# 前処理に関するアンケート

Q1. 前処理はやりたくないですか？




有効回答数 23

MS/MSユーザーズML 調査



# 前処理に関するアンケート

Q2. よく行なう前処理法は何ですか？




有効回答数 23

MS/MSユーザーズML 調査



# 前処理に関するアンケート

Q2. よく行なう前処理法は何ですか？



有効回答数 23

MS/MSユーザーズML 調査



# 生体試料直接注入の問題点

---

① 前処理カラムやカラムスイッチングが必要

② 汎用分析に適用しにくい

生体試料分析専用カラム

有機溶媒濃度に制限

リン酸緩衝液を常用（LC-MS分析が困難）

ODSが存在しない



# 生体試料直接注入の問題点 解決

---

① 前処理用カラムやカラムスイッチングは不要

② 汎用分析でも使用可能なODSカラムで


の条件を満たす分析法開発



# 新規ハイブリッド固定相の概念図


## Cadenza CD-C18

### Hydrophobic ODS Phase




## Cadenza **HS-C18**

### Hydrophobic /Hydrophilic Hybrid



# 血清直接注入による逆相グラジエント

serum protein



- 1 acyclovir ( $pK_a=2.5, 9.4$ )
- 2 nicotinamide
- 3 theophylline
- 4 ibuprofen ( $pK_a=4.3$ )
- 5 sulfamethazine ( $pK_a=7.4$ )
- 6 N-acetylprocainamide ( $pK_a=8.3$ )
- 7 carbamazepine ( $pK_a=7.0$ )
- 8 progesterone
- 9 bacitracin (MW=1307)
- 10 nortriptyline ( $pK_a=9.7$ )

---

Cadenza HS-C18, 150 x 3 mm

A: 10mM ammonium acetate

B: acetonitrile

0-75%B (0-10min)


0.4 mL/min (11MPa)

37 deg.C, 260 nm,


bovine serum 16uL (0.1-4.0  $\mu$ g)

---

# Compounds



Lansoprazole  
( Analyte )



Omeprazole  
( Internal Standard )



# Sample Preparation

*Direct Injection vs.  
Protein Precipitation*

## Direct Injection

- ↓ Plasma
- ↓ Centrifugation
- ↓ Addition of I.S.  
9:1 H<sub>2</sub>O ( I.S. ) to Plasma
- ↓ Injection

## Protein Precipitation

- ↓ Plasma
- ↓ Centrifugation
- ↓ Protein Precipitation  
4:1 ACN ( IS ) to Plasma
- ↓ Filtration
- ↓ Injection



# Analytical Conditions

## *Direct Injection vs. Protein Precipitation*

### Direct Injection

#### Column

Cadenza HS-C18  
20×4.6 mm, 3 μm ( Imtakt )  
with Guard Column

#### Mobile Phase

A, 10 mM ammonium formate  
( pH3.0 )

B, Acetonitrile

100 % A ( 0→0.5 min. )

0→100 % B ( 0.5→2.5 min. )

100 %B ( 2.5→3.5 min. )

**Flow Rate** 500 μL/min.

**Temperature** 40 deg. C

**Injection Volume** 10 μL

**MS/MS** ESI, Positive, MRM

### Protein Precipitation

#### Column

ODS Column  
20×4.6 mm, 5 μm  
without Guard Column

#### Isocratic

A, 10 mM ammonium formate  
( pH3.0 )

B, Methanol

C, Acetonitrile

A/B/C = ( 27.5 : 35.0 : 37.5 )

0 - 8.5 min.

**Flow Rate** 70 μL/min.

**Temperature** 40 deg. C


**Injection Volume** 1 μL

**MS/MS** ESI, Positive, MRM

# Chromatogram


*Direct Injection vs.  
Protein Precipitation*

LOQ, plasma



Lansoprazole

Plasma Blank




Omeprazole



# Linearity

*Direct Injection vs.  
Protein Precipitation*




10 - 3000 ng/mL, Weight  $1/x^2$ ,  $n = 3$



# Linearity

*Direct Injection vs.  
Protein Precipitation*



# Accuracy and Precision


*Direct Injection vs.  
Protein Precipitation*

	Nominal Concentration ( ng/mL )					
	10		300		3000	
<b>Accuracy ( Mean, % )</b>	<b>-1.9</b>	<b>5.5</b>	<b>4.3</b>	<b>-0.4</b>	<b>-6.4</b>	<b>0.7</b>
<b>Precision ( CV, % )</b>						
Intra-batch ( n = 3 )	<b>2.7</b>	<b>4.0</b>	<b>2.4</b>	<b>3.1</b>	<b>2.5</b>	<b>2.8</b>
Inter-batch ( n = 6 )	<b>5.0</b>	<b>6.1</b>	<b>4.0</b>	<b>5.1</b>	<b>6.6</b>	<b>4.8</b>



# Quality Control

Clinical Trial



Lansoprazole 30 mg Single Dosa ( One Healthy Adult male )

● - IS Peak Area


◆ - QC Samples ( 10, 300 and 3000 ng/mL ); QC Range = ±15 %



TOWA PHARMACEUTICAL CO., LTD.


# Longevity

Clinical Trial



# Plasma Concentrations

*Clinical Trial*




- - Direct Injection
- - Protein Precipitation

AUC - ng·h/mL  
Cmax - ng/mL



# Metabolites

Clinical Trial



Lansoprazole

Lansoprazole Sulfide

5-hydroxy Lansoprazole

Lansoprazole Sulfone



TOWA PHARMACEUTICAL CO., LTD.

# まとめ

---

**Novel Hydrophobic/Hydrophilic Hybrid ODS Column  
Cadenza HS-C18**

**Direct Injection LC-MS/MS Analysis of  
Lansoprazole in human plasma**

**Method Validation  
Clinical Trial  
Direct Injection vs. Protein precipitation**



# まとめ

---

**Novel Hydrophobic/Hydrophilic Hybrid ODS Column  
Cadenza HS-C18**

**Direct Injection LC-MS/MS Analysis of  
Lansoprazole in human plasma**

**Satisfactory**

**Direct injection vs. Protein precipitation**



# まとめ

---

**Novel Hydrophobic/Hydrophilic Hybrid ODS Column  
Cadenza HS-C18**

**Direct Injection LC-MS/MS Analysis of  
Lansoprazole in human plasma**

**Direct Injection vs. Methanol Precipitation**

**Excellent?**



# まとめ

---

**Novel Hydrophobic/Hydrophilic Hybrid ODS Column  
Cadenza HS-C18**

**Direct Injection LC-MS/MS Analysis of  
Lansoprazole in human plasma**

**Direct Injection vs. Extraction**

**Perfect?  
Satisfactory?**

